Conestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

Conestoga Capital Advisors LLC lessened its stake in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) by 21.3% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 192,274 shares of the company’s stock after selling 52,070 shares during the quarter. Conestoga Capital Advisors LLC owned about 0.36% of Alpha Teknova worth $998,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Invesco Ltd. bought a new position in Alpha Teknova in the 4th quarter valued at about $9,236,000. Bank of America Corp DE increased its stake in shares of Alpha Teknova by 1.8% during the fourth quarter. Bank of America Corp DE now owns 221,285 shares of the company’s stock worth $1,848,000 after purchasing an additional 3,904 shares during the period. Susquehanna International Group LLP increased its stake in shares of Alpha Teknova by 472.5% during the fourth quarter. Susquehanna International Group LLP now owns 209,409 shares of the company’s stock worth $1,749,000 after purchasing an additional 172,828 shares during the period. 683 Capital Management LLC acquired a new stake in Alpha Teknova during the 4th quarter worth approximately $744,000. Finally, Raymond James Financial Inc. bought a new stake in Alpha Teknova in the 4th quarter valued at $716,000. Institutional investors own 13.81% of the company’s stock.

Alpha Teknova Stock Performance

Shares of NASDAQ TKNO opened at $5.48 on Tuesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 3.94. The firm has a market cap of $292.86 million, a price-to-earnings ratio of -7.41 and a beta of 0.40. The stock’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $6.96. Alpha Teknova, Inc. has a one year low of $1.16 and a one year high of $10.37.

Alpha Teknova (NASDAQ:TKNO) last announced its earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The company had revenue of $9.60 million during the quarter, compared to analysts’ expectations of $9.41 million. On average, equities analysts forecast that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Alpha Teknova Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.